Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

Abstract

The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.

• Authors: Tina Vilsbøll
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 16 Issue 2 Pg. 231-7 (Feb 2007) ISSN: 1744-7658 [Electronic] England
• PMID: 17243943 (Publication Type: Journal Article, Review)

Chemical References

• Liraglutide
• Glucagon-Like Peptide 1

Topics

• Animals
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Drug Administration Schedule
• Glucagon-Like Peptide 1 (administration & dosage, analogs & derivatives)
• Humans
• Liraglutide